{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:54:10Z","timestamp":1793883250745,"version":"4.7.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcyt.2026.102884","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:34:10Z","timestamp":1776011650000},"page":"102884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rethinking CAR-T manufacturing paradigms: terminology, operational considerations, and economic trade-offs"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-2110","authenticated-orcid":false,"given":"Chase","family":"McCann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6961-2296","authenticated-orcid":false,"given":"Jacob","family":"Matriccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-5024","authenticated-orcid":false,"given":"Mark","family":"Lowdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiz Gerhardt","family":"Astigarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lechich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4124-782X","authenticated-orcid":false,"given":"Josephine","family":"Lembong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102884_bib0001","series-title":"Presented at Alliance for Regenerative Medicine\u2019s Advanced Manufacturing & Industrialization of the CGT Sector Workshop 2025","article-title":"ATMPs \u2013 models for distributed manufacture","author":"Lowdell","year":"2025"},{"key":"10.1016\/j.jcyt.2026.102884_bib0002","unstructured":"US Food and Drug Administration. Considerations for the design of early-phase clinical trials of cellular and gene therapy products, guidance for industry, 2015. https:\/\/www.fda.gov\/media\/106369\/download. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0003","unstructured":"US Food and Drug Administration. Current good manufacturing practice for phase 1 investigational drugs, guidance for industry, 2008. https:\/\/www.fda.gov\/media\/70975\/download. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0004","article-title":"Distributed cell therapy manufacturing trade-offs you should know about","author":"Buend\u00eda","year":"2025","journal-title":"Cell & Gene Insight"},{"key":"10.1016\/j.jcyt.2026.102884_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jcyt.2020.08.007","article-title":"Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation","volume":"23","author":"Lam","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102884_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013518","article-title":"Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery","volume":"13","author":"Stewart","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102884_bib0007","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"5","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"key":"10.1016\/j.jcyt.2026.102884_bib0008","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","article-title":"Expanding access to CAR T cell therapies through local manufacturing","volume":"41","author":"Elsallab","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102884_bib0009","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102884_bib0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","article-title":"Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T cells using the CliniMACS prodigy device at an academic medical center","volume":"20","author":"Zhu","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102884_bib0011","series-title":"Presented at Alliance for Regenerative Medicine\u2019s Advanced Manufacturing & Industrialization of the CGT Sector Workshop 2025","article-title":"The Galapagos decentralized cell therapy manufacturing platform","author":"Astigarraga","year":"2025"},{"key":"10.1016\/j.jcyt.2026.102884_bib0013","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2026.102884_bib0014","unstructured":"EudraLex: The rules governing medicinal products in the European Union, volume 4. Good Manufacturing Practice. Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products.https:\/\/health.ec.europa.eu\/medicinal-products\/eudralex\/eudralex-volume-4_en#part-iv\u2014gmp-requirements-for-advanced-therapy-medicinal-products. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0015","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.jcyt.2023.08.007","article-title":"A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy","volume":"25","author":"Wang","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102884_bib0016","unstructured":"Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos\u2019 decentralized CAR-T manufacturing network in the U.S.https:\/\/www.glpg.com\/press-releases\/galapagos-and-blood-centers-of-america-announce-strategic-collaboration-to-accelerate-galapagos-decentralized-car-t-manufacturing-network-in-the-u-s\/. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0017","unstructured":"Advanced Manufacturing Strategies to Increase the Reach of Cell and Gene Therapies. Alliance for Regenerative Medicine. 2024. https:\/\/alliancerm.org\/advanced-manufacturing-strategies\/. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0018","unstructured":"Center for Drug Evaluation and Research. US Food and Drug Administration. Distributed manufacturing and point-of-care manufacturing of drugs.2022. https:\/\/www.regulations.gov\/document\/FDA-2022-N-2316-0002. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0019","unstructured":"Center for Drug Evaluation and Research. US Food and Drug Administration. Distributed manufacturing of drugs: stakeholder feedback and action plan. 2023. https:\/\/www.fda.gov\/media\/173449\/download. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0020","unstructured":"US Food and Drug Administration. Manufacturing changes and comparability for human cellular and gene therapy products, draft guidance, 2023. https:\/\/www.fda.gov\/media\/170198\/download. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0021","unstructured":"US Food and Drug Administration. Flexible requirements for cell and gene therapies to advance innovation, 2026.https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/flexible-requirements-cell-and-gene-therapies-advance-innovation. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0022","unstructured":"UK Decentralised manufacture hub. https:\/\/www.gov.uk\/government\/collections\/decentralised-manufacture-hub. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0023","unstructured":"Foster, J. Understanding COGS and quantifying the benefits of automation. Presented at Alliance for Regenerative Medicine\u2019s Advanced Manufacturing Workshop 2024, Rockville, MD; 16th-17th May, 2024."},{"key":"10.1016\/j.jcyt.2026.102884_bib0024","unstructured":"Bonnot R, Srivastava P, Kaman M, Yu T 2024. Decentralized manufacturing: unlocking CAR-T\u2019s potential. ZS. https:\/\/www.zs.com\/content\/dam\/pdfs\/Decentralized-manufacturing.pdf. Accessed April 12, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0025","unstructured":"Abraham, E Getting autologous therapies COGs down from \u223c$100kto \u223c$30k by use of transformative processes and technologies. Presented at Alliance for Regenerative Medicine\u2019s Advanced Manufacturing Workshop 2024, Rockville, MD; 16th-17th May, 2024."},{"key":"10.1016\/j.jcyt.2026.102884_bib0026","unstructured":"Bonnot R, Srivastava P, Kaman M, Yu T. Decentralized manufacturing: unlocking CAR-T's potential. ZS White Paper. 2024. https:\/\/www.zs.com\/content\/dam\/pdfs\/Decentralized-manufacturing.pdf. Accessed May 11, 2026."},{"key":"10.1016\/j.jcyt.2026.102884_bib0027","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.18609\/cgti.2018.108","article-title":"The long road to affordability: a cost of goods analysis for an autologous CAR-T process","volume":"4","author":"Spink","year":"2018","journal-title":"Cell Gene Therapy Insights"},{"key":"10.1016\/j.jcyt.2026.102884_bib0028","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","article-title":"Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel","volume":"15","author":"Dulobdas","year":"2025","journal-title":"Blood Cancer J"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:27:27Z","timestamp":1783337247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926008455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1465324926008455"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102884","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking CAR-T manufacturing paradigms: terminology, operational considerations, and economic trade-offs","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102884"}}